US regulators weigh access to controversial peptides amid ethics scrutiny
The Pharmacy Compounding Advisory Committee convenes this week to determine if seven peptides should be available via licensed pharmacies, despite agency concerns over safety and evidence.
The US Food and Drug Administration’s Pharmacy Compounding Advisory Committee is meeting on Thursday and Friday to determine whether seven specific peptides should be made available through licensed compounding pharmacies for patients with prescriptions. The review addresses surging demand driven by social media trends and endorsements from Health Secretary Robert F Kennedy Jr, despite FDA concerns regarding insufficient evidence of safety and effectiveness.
The seven peptides under review include BPC-157, TB-500, and KPV, which are marketed for conditions such as ulcerative colitis, wound healing, inflammatory conditions, obesity, migraines, chronic pain, insomnia, and opioid withdrawal. Peptides are short chains of amino acids that occur naturally in the body and help regulate biological processes, though the compounds under scrutiny differ from established peptide-based medicines such as the GLP-1 weight-loss drugs Ozempic and Wegovy.
In documents ahead of the meeting, the FDA stated that there is little evidence supporting the safety or effectiveness of these compounds, citing inadequate human clinical trials and concerns regarding quality, stability, and consistency. The agency’s caution comes as demand for the peptides has exploded, propelled by social media influencers, the “looksmaxxing” beauty trend, and repeated endorsements from Health Secretary Robert F Kennedy Jr, who has claimed he has used them with “really good effect” and argued that current restrictions have pushed consumers into an unregulated grey market.
Industry groups argue that allowing licensed pharmacies to compound peptides would enable greater oversight of prescriptions and quality standards. However, the composition of the advisory committee itself has drawn scrutiny. According to the Associated Press, seven of the 14 members have ties to businesses or clinics involved in peptide therapies, including doctors who sell peptide injections and pharmacist Tennessee State Senator Bobby Harshbarger, whose family owns a pharmacy selling compounded medications.
The Department of Health and Human Services has defended the panel’s composition, stating that every member underwent the same ethics review required for FDA advisory committees and that those failing to meet federal ethics requirements were removed. While the panel’s recommendations are not binding, they are expected to help shape the FDA’s final decision on the availability of these compounds.
